IOM Report Advises FDA, NIH To Spur Innovation For Rare Disease Devices
This article was originally published in The Gray Sheet
Executive Summary
FDA and NIH should consider options for stimulating high-priority device innovations to treat rare diseases, including the creation of NIH awards, R&D tax credits and "inducement" prizes, according to an Institute of Medicine report